sarpogrelate has been researched along with Insulin Resistance in 5 studies
sarpogrelate: structure given in first source
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 7.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| "Indices of insulin resistance (IR) (fasting immunoreactive insulin (IRI) and calculated homeostasis model assessment (HOMA-R)) and adiponectin were measured before and after 2 weeks of sarpogrelate administration (300 mg/day) in 24 patients (19 men, 76+/-9 years) with PAD." | 5.12 | Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. ( Eguchi, M; Hase, M; Hashimoto, A; Kokubu, N; Miura, T; Nagao, K; Nakata, T; Shimamoto, K; Tsuchihashi, K; Tsuzuki, M; Ura, N; Wakabayashi, C; Wakabayashi, T; Yuda, S, 2006) |
| " Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined." | 3.72 | Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004) |
| "Nonalcoholic fatty liver disease (NAFLD) is increasing in worldwide prevalence, closely tracking the obesity epidemic, but specific pharmaceutical treatments for NAFLD are lacking." | 1.48 | Serotonin signals through a gut-liver axis to regulate hepatic steatosis. ( Bang, G; Choi, C; Choi, W; Han, KH; Hwang, I; Jeong, JS; Ju, YS; Karsenty, G; Kim, H; Kim, YH; Lee, HW; Lim, A; Namkung, J; Park, HJ; Park, JY; Park, S; Suh, JM; Yadav, VK, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, W | 1 |
| Namkung, J | 1 |
| Hwang, I | 1 |
| Kim, H | 2 |
| Lim, A | 1 |
| Park, HJ | 1 |
| Lee, HW | 1 |
| Han, KH | 1 |
| Park, S | 2 |
| Jeong, JS | 1 |
| Bang, G | 1 |
| Kim, YH | 1 |
| Yadav, VK | 1 |
| Karsenty, G | 1 |
| Ju, YS | 1 |
| Choi, C | 1 |
| Suh, JM | 1 |
| Park, JY | 1 |
| Nagayama, D | 1 |
| Ohira, M | 1 |
| Saiki, A | 1 |
| Shirai, K | 1 |
| Tatsuno, I | 1 |
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
| Takishita, E | 1 |
| Takahashi, A | 1 |
| Harada, N | 1 |
| Yamato, M | 1 |
| Yoshizumi, M | 1 |
| Nakaya, Y | 1 |
| Kokubu, N | 1 |
| Tsuchihashi, K | 1 |
| Yuda, S | 1 |
| Hase, M | 1 |
| Eguchi, M | 1 |
| Wakabayashi, T | 1 |
| Hashimoto, A | 1 |
| Nakata, T | 1 |
| Miura, T | 1 |
| Ura, N | 1 |
| Nagao, K | 1 |
| Tsuzuki, M | 1 |
| Wakabayashi, C | 1 |
| Shimamoto, K | 1 |
2 trials available for sarpogrelate and Insulin Resistance
| Article | Year |
|---|---|
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Female; Homeostasis; Humans; | 2006 |
3 other studies available for sarpogrelate and Insulin Resistance
| Article | Year |
|---|---|
Serotonin signals through a gut-liver axis to regulate hepatic steatosis.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulati | 2018 |
Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients.
Topics: Aged; Ankle Brachial Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relation | 2014 |
Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Insulin Resistan | 2004 |